Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Department of Urology, Cairo University, Cairo, Egypt.
J Urol. 2021 Aug;206(2):229-239. doi: 10.1097/JU.0000000000001714. Epub 2021 Mar 29.
Despite general indolence of small renal masses and no known adversity from treatment delays, broad usage of active surveillance as a means to risk-stratify patients with small renal masses for more selective treatment has not been studied. We describe outcomes for a novel approach in which active surveillance was recommended to all patients with small renal masses lacking predefined progression criteria for intervention.
All nondialysis dependent patients with nonmetastatic small renal masses seen by 1 urologist at a comprehensive cancer center during January 2013-September 2017 were managed with active surveillance if standardized progression criteria for intervention were absent, with delayed intervention recommended only upon progression criteria for intervention development. Progression criteria for intervention were defined prospectively as small renal mass-related symptoms, unfavorable histology, cT3a stage or either of the following without benign neoplastic biopsy histology: longest tumor diameter >4 cm; growth rate >5 mm/year for longest tumor diameter ≤3 cm or >3 mm/year for longest tumor diameter >3 cm.
In all, 96% (123/128) of patients with small renal masses lacked progression criteria for intervention at presentation and underwent active surveillance. With median/mean 31/34 months followup, none developed metastasis and 30% (37/123) developed progression criteria for intervention, 78% (29/37) of whom underwent delayed intervention. One (1%) patient crossed over to delayed intervention without progression criteria for intervention. Three-year progression criteria for intervention-free and delayed intervention-free rates were 72% and 75%, respectively. Delayed intervention resections were enriched (62%) for pT3 and/or nuclear grade 3-4 malignant pathology, with no benign resections.
Active surveillance using predefined progression criteria for intervention in otherwise unselected patients with small renal masses allows intervention to be focused on at-risk small renal masses with common adverse pathology, avoiding treatment for most patients with small renal masses. Long-term delayed intervention and oncologic safety require study.
尽管小肾肿瘤通常惰性且治疗延迟不会带来已知的不良后果,但广泛应用主动监测作为一种风险分层方法,对小肾肿瘤患者进行更有选择性的治疗,尚未得到研究。我们描述了一种新方法的结果,该方法建议所有缺乏干预性进展标准的小肾肿瘤患者进行主动监测,如果不存在标准化的干预进展标准,则建议仅在出现干预进展标准时延迟干预。干预进展标准前瞻性地定义为小肾肿瘤相关症状、不良组织学、cT3a 期或以下任何一种情况而无良性肿瘤活检组织学:最长肿瘤直径>4cm;最长肿瘤直径≤3cm 时生长速度>5mm/年,最长肿瘤直径>3cm 时生长速度>3mm/年。
2013 年 1 月至 2017 年 9 月期间,在一家综合癌症中心由 1 位泌尿科医生诊治的所有非透析依赖的非转移性小肾肿瘤患者,如果缺乏干预性进展标准,则采用主动监测,如果不存在标准化的干预进展标准,则建议仅在出现干预进展标准时延迟干预。干预进展标准前瞻性地定义为小肾肿瘤相关症状、不良组织学、cT3a 期或以下任何一种情况而无良性肿瘤活检组织学:最长肿瘤直径>4cm;最长肿瘤直径≤3cm 时生长速度>5mm/年,最长肿瘤直径>3cm 时生长速度>3mm/年。
共有 128 例小肾肿瘤患者的 96%(123/128)在就诊时缺乏干预性进展标准,接受了主动监测。中位/平均随访 31/34 个月,无患者发生转移,30%(37/123)出现干预进展标准,其中 78%(29/37)接受了延迟干预。1 例(1%)患者在没有干预进展标准的情况下接受了延迟干预。3 年的干预无进展和延迟干预无进展率分别为 72%和 75%。延迟干预切除标本中富含 pT3 和/或核分级 3-4 级恶性病理,无良性切除标本。
在未选择的小肾肿瘤患者中,使用预设的干预进展标准进行主动监测可以将干预重点集中在具有常见不良病理的高危小肾肿瘤上,避免对大多数小肾肿瘤患者进行治疗。长期延迟干预和肿瘤安全性需要进一步研究。